Imugene Ltd · ASX:IMU
Imugene — Investor Presentation (July 2025)
37 slides from Imugene's investor presentation, Jul 16, 2025
Slide 1: Innovation in Cancer Treatment
ASX:IMU Capital Raising Presentation Innovation in July 2025 Cancer Treatment 1 Release authorised by the Managing Director and Chief Executive Officer, Imugene Limited.
Slide 2: Disclaimer
Disclaimer The information in this presentation does not constitute personal Neither the Company nor any of its directors, officers, employees, investment advice. The presentation is not intended to be advisers, associated persons or subsidiaries are liable for any direct, comprehensive or provide a
Slide 3: Executive summary
Executive summary Up to A$37.5m capital raising coinciding with release of new azer-cel data from additional 5 patients; Ph1b trial now at 75% Overall Response rate – company to pursue registrational trial pathway with FDA • Clinical stage immuno-oncology company; we develop immunotherapies that see
Slide 4: Three Novel Cancer Technologies In Clinical Trials
Three Novel Cancer Technologies In Clinical Trials onCARlytics CD19 CF33 Oncolytic Virus azer-cel CD19 allo CAR T expressing virus VAXINIA MAST Trial OASIS Trial Phase 1b Phase 1 Phase 1 Novel virus which acts as a CD19 target in Novel cancer killing virus Off-the-shelf drug, aka allogeneic solid ca
Slide 5: Azer-Cel CD19 Allo CAR T for blood cancer
Azer-Cel CD19 Allo CAR T for blood cancer 5
Slide 6: Auto CAR-T Cell Therapy Overview
Auto CAR-T Cell Therapy Overview CAR-T cell therapy is an emerging form personalised medicine which uses a patient’s immune cells (T-Cells) to fight cancer • T cells are naturally occurring white blood cells that are responsible for destroying any infected or abnormal cells, including cancer, as par
Slide 7: Two Types of CAR-T Cell Therapy: Auto and Allo
Two Types of CAR-T Cell Therapy: Auto and Allo Potential First-in-class Off-the-shelf Allogeneic CAR-T Cell Therapy significantly differentiated from approved Auto CAR-T Therapies Autologous – 4+ FDA approved products in CD19 • Auto CAR-T cells are made from the patient’s own T-cells • Highly person
Slide 8: CD19 Auto CAR-T Market is Large and Growing
CD19 Auto CAR-T Market is Large and Growing 4 FDA Approved CD19 CAR-T therapies generating >US$3bn (CY18-24 49% CAGR) Global CD19 CAR-T market is large and growing $3.5 4 Approved FDA CAR-T (Autologous Only) Selling Price $3.0 First FDA Approved (USD$’000s) Drug Company Approval Cancers per $2.5 Tre
Slide 9: Recent Deals in CAR-T Cell Therapy
Recent Deals in CAR-T Cell Therapy Big pharma continue to pursue promising early/mid stage CAR-T therapies in US$1bn+ transactions Date Deal Summary Involved Parties Technology Indication Stage Valuation (USD$) Phase 1 and June Acquistion of Capstan by Up to $2.1B (undisclosed CD19 in vivo CAR Auto-
Slide 10: Introduction to azer-cel
Introduction to azer-cel On-Demand CAR T Therapy 1 2 Azer-cel is an ‘off-the-shelf’ CD19 Allo Azer-cel is designed to address high CAR T drug and growing unmet need in the post Azercabtagene zapreleucel (azer-cel) is an auto CAR T setting of Diffuse Large B Cell Lymphoma (DLBCL) and CAR T allogeneic
Slide 11: Compelling Phase 1b Data
Compelling Phase 1b Data 75% Overall Response Rate, 55% Complete Response Rates Complete Best Date of Evaluable Overall Response KEY INFO Treatment N Response Durabilit Release patients (CR) At Day y (Time of • Phase 1b trial continues to Rate (ORR) 60 response) enrol patients across leading Lymphod
Slide 12: Compelling Phase 1b Data
Compelling Phase 1b Data 75% Overall Response; 55% Complete Response Rates Complete Evaluable Overall Response2 Best Durability Treatment N Response3 (CR) patients Rate (ORR) (Time of response) Day 60 scan Lymphodepletion (LD)1 Diffuse Large B-Cell Lymphoma 9 (75%) 6 (55%) >450 days on +azer-cel 12
Slide 13: Azer-cel 75% Overall Response Rate and 55% Complete Response
Azer-cel 75% Overall Response Rate and 55% (6/11) Complete Response N=12 Best Response CR CR CR CR CR CR PR PR PR SD SD PD Durability 450+ 330+ *190+ 90 90 60+ 60+ 60 30+ Days Days Days Days Days Days Days Days Days *Allo transplant at Day 148 Overall Response Rate (ORR): the proportion of patients
Slide 14: Comparison to Existing Approved Auto CAR-T Therapies
Comparison to Existing Approved Auto CAR-T Therapies Initial azer-cel Ph 1b data compelling when compared to approved Auto CAR-T treatments Product Indication Complete Best Durability of FDA benchmark1 for approval in heavily pre-treated Response (CR) Response3 (DoR) rate at Day 60 2 (3L+) Diffuse L
Slide 15: Patient Case Study: Cancer Free for 450+ Days
Patient Case Study: Cancer Free for 450+ Days Complete Response for an azer-cel patient that failed 4 prior lines of therapy including auto CAR-T. Durability of Response now out to 450+ days and patient currently remains cancer free Tumour Tumour-free Baseline Day 450+ Patient Treatment Summary • 47
Slide 16: Proposed Clinical Pathway: Azer-cel Allogeneic CD19 CAR T
Proposed Clinical Pathway: Azer-cel Allogeneic CD19 CAR T Opportunity to initiate a pivotal clinical trial in 2026 • A Phase 1a clinical trial in Lymphoma & Leukaemia with 84 patients was completed by Precision Biosciences in 2023 and delivered promising results • Imugene is currently undertaking a
Slide 17: Azer-cel Commercialisation Opportunity
Azer-Cel Commercialisation Opportunity $2bn+ p.a US market opportunity with no approved CAR-T therapies in rare lymphomas and relapsed CAR-T therapy patients AZER CEL US INCIDENCE 1 ELIGIBLE FOR CAR T 2 MARKET OPPORTUNITY MZL, 4,500 ($Millions) 3 WM, 1,000 DLBCL/HGBCL, MZL, 1,200 800 MZL, $480 DLBCL
Slide 18: Azer-cel's Strategic Appeal
Azer-cel’s Strategic Appeal Off-the-Shelf CAR-T Cell Therapy delivering scalable and effective treatment for blood cancers • Ability for azer-cel to be First-in-class, Off-the-shelf (allogeneic) CAR-T cell therapy • Promising Phase 1b data – 75% Overall Response rate/55% Complete Response rate in th
Slide 19: Experienced Leadership Team has Brought 18+ FDA-Approved Drugs to Market
Experienced Leadership Team has Brought 18+ FDA- Approved Drugs to Market Darren Keamy Chief Financial Officer and Company Secretary BOARD OF DIRECTORS Leslie Chong John Byon, MD, PhD Bradley Glover, Ursula McCurry Paul Hopper Chief Executive Officer Chief Medical Officer PhD, MBA Chief Clinical & M
Slide 20: Expected Key Catalysts
Expected Key Catalysts Rich News flow 12 months ahead across Imugene’s programs Key Achievements Expected Upcoming Milestones azer-cel azer-cel January 2025: First Aus site 3Q CY25 opened for DLBCL clinical trial and • Release of additional Phase 1b azer-cel data first DLBCL patient dosed in AUS • R
Slide 21: Investment Highlights
Investment Highlights Clinical stage immuno-oncology company with broad platforms 01 that provide multiple shots on goal Targeting large markets with no current treatments and 02 significant unmet need Compelling preliminary data from azer-cel with material read-outs expected in the near term – pote
Slide 22: Corporate Snapshot
Corporate Snapshot Stock Code ASX: IMU Top 15 Shareholders* Market Capitalisation (14 July 2025) A$93.3 million Mr Paul Hopper 12,057,824 5.49% Average Monthly Trading Volume 12 million shares Mann Family 6,764,706 3.08% Cash Balance (30 June 2025)* $27.9 million Vanguard Group 6,090,122 2.77% No of
Slide 23: Capital Raising
ay IMUGENE Developing Cancer Immunotherapies apital Raising
Slide 24: Capital Raising Summary
Capital Raising Summary Capital raising of up to approximately A$37.5 million to fund the azer-cel program through to a pivotal clinical trial Placement • Placement to raise approximately A$22.5 million (Placement) • Approximately 68.2m new shares (New Shares) issued under the Company’s existing pla
Slide 25: Indicative Timetable
Indicative Timetable Key Events Date Trading halt Monday, 14 July 2025 Bookbuild Opens Monday, 14 July 2025 Record Date for SPP 7:00pm (AEST) Tuesday, 15 July 2025 Results of Placement announced & Shares resume trading on ASX Wednesday, 16 July 2025 Placement settlement of New Shares Wednesday, 23 J
Slide 26: Sources And Use Of Funds
Sources And Use Of Funds Funding to support the azer-cel program, other R&D programs, general and working capital Sources A$m Cash at Hand as at 30 June 20251 $27.9m • Post completion of the Offer, Imugene will have a pro-forma cash balance as at 30 June 2025 of $64 million1 (net of Offer Offer proc
Slide 27: Appendix
Developing Cancer Immunotherapies APPENDIX 27
Slide 28: CF33 VAXINIA Oncolytic (Anti-Cancer) Virus
CF33 VAXINIA Oncolytic (Anti-Cancer) Virus 28
Slide 29: What is the CF33 Virus
Cowpox Western WHAT IS THE Racoon Smallpox Reserve LC Elstree virus virus CF33 VIRUS Rabbit Engineered next- generation virus CF33 A synthetic virus– it does not exist in nature CF33 is an anti- cancer virus which onCARlytics CF33 Oncolytic Virus only attacks CD19 THERAPY VAXINIA MAST cancer cells C
Slide 30: OnCARlytics
Gg) onCARlytics IMUGENE OnCARlytics
Slide 31: What is Imugene's onCARlytics CD19 expressing virus?
What is Imugene’s onCARlytics CD19 expressing virus? Imugene’s novel onCARlytics CD19 virus, makes a solid cancer “resemble” a CD19 blood cancer cell, and lures FDA approved anti-CD19 CAR T drugs, to attack them IMU’s CD19 virus causes solid cancers Solid cancers do not have the CD19 This makes them
Slide 32: OASIS Phase 1 Open Label Trial with CD19 Virus and Blinatumomab
OASIS Phase 1 Open Label Trial with CD19 Virus and Blinatumomab Combination treatment for solid cancers + onCARlytics CD19 Bispecific CD19 virus antibody Recruiting up to 40 patients Multiple trial sites including; University of Cincinnati, MD Anderson Cancer Centre and City of Hope 32
Slide 33: Variety of Approved Therapies available for combination with onCARlytics
Variety of Approved Therapies available for combination with onCARlytics OnCARlytics could become the preferred partner for Combination Opportunities CD19 therapies in solid tumours (~90% of cancer market) First Approved Blood Product Company Approval Target Cancers cancers R/R LBCL, 10% 2021 CD19 A
Slide 34: Key Risk Factors
Key Risk Factors Specific investment risks meet commercialisation goals. If Imugene is unable to find a partner, it would be required to develop and commercialise potential products at its own expense. • IMU’s products in development and not approved for commercial sale – This may place significant
Slide 35: Key Risk Factors
Key Risk Factors General investment risks • Litigation - There is a risk that the Company may in future be the subject of or required to commence litigation. There is, however, no litigation, mediation, • Investment risks - The price of the Shares might rise or fall and they might trade conciliation
Slide 36: Foreign Offer Restrictions
Foreign Offer Restrictions This presentation is for information purposes only and is not an invitation or offer 1. is an investment business within the meaning of clause 37 of Schedule 1 of the of securities for subscription, purchase or sale in any jurisdiction. The distribution FMC Act; of this pr
Slide 37: ASX : IMU imugene.com
ASX : IMU shareholderenquiries@imugene.com imugene.com 37